Evidence map›Paper›PMID 39198495›Full record

ArticleScientific reports2024

Pharmacokinetics of extended-release clarithromycin in patients with Mycobacterium ulcerans infection.

Sandor-Adrian Klis, Ymkje Stienstra, Kabiru M Abass, Justice Abottsi, Samuel O Mireku, Jan-Willem Alffenaar, Tjip S van der Werf

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Sandor-Adrian KlisDepartment of Internal Medicine-Infectious Diseases, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Ymkje StienstraDepartment of Internal Medicine-Infectious Diseases, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Kabiru M AbassAgogo Presbyterian Hospital, Agogo, Ghana.
Justice AbottsiAgogo Presbyterian Hospital, Agogo, Ghana.
Samuel O MirekuAgogo Presbyterian Hospital, Agogo, Ghana.
Jan-Willem AlffenaarThe University of Sydney Institute for Infectious Diseases, Sydney, NSW, Australia.
Tjip S van der WerfDepartment of Internal Medicine-Infectious Diseases, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. t.s.van.der.werf@umcg.nl.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Clarithromycin extended-release (CLA-ER) was used as companion drug to rifampicin (RIF) for Mycobacterium ulcerans infection in the intervention arm of a WHO drug trial. RIF enhances CYP3A4 metabolism, thereby reducing CLA serum concentrations, and RIF concentrations might be increased by CLA co-administration. We studied the pharmacokinetics of CLA-ER at a daily dose of 15 mg/kg combined with RIF at a dose of 10 mg/kg in a subset of trial participants, and compared these to previously obtained pharmacokinetic data. Serial dried blood spot samples were obtained over a period of ten hours, and analyzed by LC-MS/MS in 30 study participants-20 in the RIF-CLA study arm, and 10 in the RIF-streptomycin study arm. Median CLA C

Indexed as

Buruli UlcerClarithromycinDelayed-Action PreparationsMycobacterium ulceransRifampinAdultAgedAnti-Bacterial AgentsArea Under CurveFemaleHumansMaleMiddle AgedTandem Mass SpectrometryYoung AdultAnti-Bacterial AgentsClarithromycinDelayed-Action PreparationsRifampin

Identifiers

PMID39198495
PMCPMC11358409

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.